TRAP1: a viable therapeutic target for future cancer treatments?

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Heat Shock Protein 90 (HSP90) molecular chaperones, including HSP90α, HSP90β, GRP94, and TRAP1, are validated anticancer targets.
• Existing HSP90 inhibitors often fail due to toxicity and lack of specificity among HSP90 paralogs, stemming from high structural homology.
• TRAP1's specific role in tumor development and progression across various human malignancies necessitates focused therapeutic strategies.

Purpose of the Study:

• To review the significance of TRAP1 in cancer, examining its dual oncogenic/oncosuppressive functions.
• To explore the rationale and current strategies for targeting TRAP1, particularly for compartmentalized inhibition within mitochondria.
• To highlight TRAP1 as a potential therapeutic target in oncology.

Main Methods:

• Literature review of TRAP1's role in human carcinogenesis.
• Analysis of strategies for TRAP1-specific inhibition.
• Examination of TRAP1's context-dependent functions in cancer cells.

Main Results:

• TRAP1 exhibits multifaceted and context-dependent roles in cancer, acting as both an oncogene and oncosuppressor.
• Evidence supports TRAP1's involvement in human carcinogenesis, positioning it as a promising therapeutic target.
• Mitochondrial compartmentalized inhibition strategies are being explored for TRAP1 targeting.

Conclusions:

• TRAP1 targeting presents a promising avenue for cancer therapy, supported by growing evidence of its role in carcinogenesis.
• Future drug discovery must enhance selectivity and specificity for TRAP1 over other HSP90 paralogs.
• Identifying specific human malignancies suitable for TRAP1-targeted therapy is crucial for clinical success.